Bristol Myers Squibb (BMY) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $129B
- As of Nov 5, 2026
- P/E
- 13.96x
- Trailing twelve months
- P/B
- 5.51x
- Latest reported equity
- P/S
- 2.58x
- Trailing twelve months
- ROE
- 39.5%
- Trailing twelve months
- Dividend yield
- 3.94%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $129B
- As of Nov 5, 2026
- P/E
- 13.96x
- Trailing twelve months
- P/B
- 5.51x
- Latest reported equity
- P/S
- 2.58x
- Trailing twelve months
- ROE
- 39.5%
- Trailing twelve months
- Dividend yield
- 3.94%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
13.96x
P/B
5.51x
P/S
2.58x
Earnings and dividend metrics▾
Earnings
EPS
$4.52
Earnings per share
BPS
$11.45
Book value per share
ROE
39.5%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $4.52 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $11.45 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 39.5%.
Dividends
Yield
3.94%
Dividend per share
$2.49
Payout ratio
54.6%
Consecutive years
19+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $249.00 before tax.
- Payout ratio — 54.6% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 19 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 6.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $12.2B+6.9%
$11.9B
Jul–Sep '24
$12.2B
Jul–Sep '25
$13.1B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share decreased 2.8% from the same quarter a year earlier.
- Revenue increased 6.9% from the same quarter a year earlier.
- Net income decreased 1.8% from the same quarter a year earlier.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Lenkowsky AdamEVP, Chief Commercial Officer · Nov 3, 2026Shares withheld for taxes3,848 shares · $237KAvg. price $61.7123,380 shares held after
- Lenkowsky AdamEVP, Chief Commercial Officer · Nov 3, 2026Option exercise7,522 shares · $0Avg. price $027,228 shares held after
- Shanahan KarinEVP, Chief Supply Chain & Ops · Nov 1, 2026Shares withheld for taxes3,213 shares · $201KAvg. price $62.4828,956 shares held after
- Meyers Gregory ScottEVP, Chief Digital & Tech Off. · Nov 1, 2026Shares withheld for taxes2,665 shares · $167KAvg. price $62.4833,977 shares held after
- BOERNER CHRISTOPHER S.Chief Executive Officer · Nov 1, 2026Shares withheld for taxes1,724 shares · $108KAvg. price $62.4823,097 shares held after
- BOERNER CHRISTOPHER S.Chief Executive Officer · Nov 1, 2026Option exercise2,964 shares · $0Avg. price $024,415 shares held after
- BOERNER CHRISTOPHER S.Chief Executive Officer · Nov 1, 2026Other406 shares · $0Avg. price $024,821 shares held after
- Meyers Gregory ScottEVP, Chief Digital & Tech Off. · Nov 1, 2026Option exercise6,281 shares · $0Avg. price $036,642 shares held after
- Shanahan KarinEVP, Chief Supply Chain & Ops · Nov 1, 2026Option exercise6,281 shares · $0Avg. price $032,169 shares held after
- Gallman CariEVP, General Counsel · Oct 2, 2026Shares withheld for taxes2,332 shares · $143KAvg. price $61.1515,876 shares held after
- Gallman CariEVP, General Counsel · Oct 2, 2026Option exercise4,559 shares · $0Avg. price $018,208 shares held after
- Massacesi CristianEVP,Chief Med Offr,Head of Dev · Sep 9, 2026Open-market sale6,249 shares · $403KAvg. price $64.5718,748 shares held after
- Short Bartie WendyEVP, Corporate Affairs · Sep 1, 2026Option exercise1,236 shares · $83KAvg. price $66.9213,317 shares held after
- Short Bartie WendyEVP, Corporate Affairs · Sep 1, 2026Shares withheld for taxes633 shares · $42KAvg. price $66.9212,684 shares held after
- Holzer Phil MSVP and Controller · Aug 25, 2026Open-market sale500 shares · $34KAvg. price $67.516,862 shares held after
- Massacesi CristianEVP,Chief Med Offr,Head of Dev · Aug 1, 2026Shares withheld for taxes26,175 shares · $1.7MAvg. price $65.3124,997 shares held after
- Gallman CariEVP, General Counsel · Aug 1, 2026Shares withheld for taxes543 shares · $35KAvg. price $65.3113,649 shares held after
- Gallman CariEVP, General Counsel · Aug 1, 2026Option exercise1,061 shares · $0Avg. price $014,192 shares held after
- Massacesi CristianEVP,Chief Med Offr,Head of Dev · Aug 1, 2026Option exercise51,172 shares · $0Avg. price $051,172 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QBMS said its Q3 2026 revenues rose 7%, and year-to-date revenues rose 5%. The company said higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis were partially offset by generic erosion across the rest of the Legacy Portfolio.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KThe company said its total revenues for Q3 2026 rose to $13,069 million from $12,222 million a year earlier, an increase of 7%. Growth Portfolio revenues increased 12% to $7.7 billion, and Legacy Portfolio revenues increased 1% to $5.4 billion.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KBristol Myers Squibb said in its 2025 highlights that Growth Portfolio sales increased 17% for the 9 months ended September 30, 2025 compared with the prior-year period, and that it had 4 assets with annualized sales exceeding $1B based on 3Q 25 worldwide revenue.Published Oct 3, 2026 · Filed Jan 12, 2026Read the summary →
- BMS said its Q3 2026 revenues rose 7%, and year-to-date revenues rose 5%. The company said higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis were partially offset by generic erosion across the rest of the Legacy Portfolio.Read the full analysis →
- The company said its total revenues for Q3 2026 rose to $13,069 million from $12,222 million a year earlier, an increase of 7%. Growth Portfolio revenues increased 12% to $7.7 billion, and Legacy Portfolio revenues increased 1% to $5.4 billion.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Bristol Myers Squibb (BMY) stock information
NYSE
Bristol Myers Squibb (BMY) is listed on NYSE. Its market capitalization is about $129B. On trailing-twelve-month earnings the P/E ratio is 13.96, and the P/B ratio is 5.51. Return on equity is 39.5%. These figures are computed in-house from official filings and are reference information only.
Bristol Myers Squibb — frequently asked questions
- What is the P/E ratio of Bristol Myers Squibb (BMY)?
- On a trailing-twelve-month basis, BMY trades at a P/E ratio of 13.96. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Bristol Myers Squibb?
- BMY has a market capitalization of about $129B. The figure moves with the share price and is refreshed each trading day.
- Does Bristol Myers Squibb pay a dividend?
- BMY has a dividend yield of about 3.94%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.